OBJECTIVES: Dipeptidyl peptidase IV (DPPIV)/CD26 is a cell surface aminopeptidase. This study investigated the expression and localization of DPPIV in endometrial endometrioid adenocarcinomas of different grades. STUDY DESIGN: Immunohistochemical analysis was performed by using DPPIV and regulated on activation, normal T-cell expressed and secreted (RANTES) specific monoclonal antibodies. Cell proliferation was evaluated by bromodeoxyuridine (BrdU) uptake assay. RESULTS: Immunohistochemical analyses showed that DPPIV was strongly or moderately stained in glandular cells of the normal secretory phase. In endometrial adenocarcinoma, the DPPIV expression decreased with advancing grade (P <.01). Furthermore, RANTES, one of the possible DPPIV substrates, was highly expressed in all grades of endometrial adenocarcinoma cells. The addition of RANTES to endometrial adenocarcinoma cells increased proliferation in a concentration-dependent manner. CONCLUSION: DPPIV is expressed in normal endometrial glandular cells, but its expression in endometrial adenocarcinoma is down-regulated with increasing grade. Our data also suggest a regulatory role of this ectoenzyme in neoplastic transformation and progression of endometrial adenocarcinomas possibly by degrading certain bioactive peptides such as RANTES.
OBJECTIVES:Dipeptidyl peptidase IV (DPPIV)/CD26 is a cell surface aminopeptidase. This study investigated the expression and localization of DPPIV in endometrial endometrioid adenocarcinomas of different grades. STUDY DESIGN: Immunohistochemical analysis was performed by using DPPIV and regulated on activation, normal T-cell expressed and secreted (RANTES) specific monoclonal antibodies. Cell proliferation was evaluated by bromodeoxyuridine (BrdU) uptake assay. RESULTS: Immunohistochemical analyses showed that DPPIV was strongly or moderately stained in glandular cells of the normal secretory phase. In endometrial adenocarcinoma, the DPPIV expression decreased with advancing grade (P <.01). Furthermore, RANTES, one of the possible DPPIV substrates, was highly expressed in all grades of endometrial adenocarcinoma cells. The addition of RANTES to endometrial adenocarcinoma cells increased proliferation in a concentration-dependent manner. CONCLUSION:DPPIV is expressed in normal endometrial glandular cells, but its expression in endometrial adenocarcinoma is down-regulated with increasing grade. Our data also suggest a regulatory role of this ectoenzyme in neoplastic transformation and progression of endometrial adenocarcinomas possibly by degrading certain bioactive peptides such as RANTES.
Authors: Rajesh Mohandas; Laura Sautina; Elaine Beem; Anna Schuler; Wai-Yan Chan; John Domsic; Robert McKenna; Richard J Johnson; Mark S Segal Journal: Exp Cell Res Date: 2014-06-09 Impact factor: 3.905
Authors: Fiona M Keane; Tsun-Wen Yao; Stefanie Seelk; Margaret G Gall; Sumaiya Chowdhury; Sarah E Poplawski; Jack H Lai; Youhua Li; Wengen Wu; Penny Farrell; Ana Julia Vieira de Ribeiro; Brenna Osborne; Denise M T Yu; Devanshi Seth; Khairunnessa Rahman; Paul Haber; A Kemal Topaloglu; Chuanmin Wang; Sally Thomson; Annemarie Hennessy; John Prins; Stephen M Twigg; Susan V McLennan; Geoffrey W McCaughan; William W Bachovchin; Mark D Gorrell Journal: FEBS Open Bio Date: 2013-12-08 Impact factor: 2.693
Authors: Heae Surng Park; Hyun Yang Yeo; Hee Jin Chang; Kyung-Hee Kim; Ji Won Park; Byung Chang Kim; Ji Yeon Baek; Sun Young Kim; Dae Yong Kim Journal: Yonsei Med J Date: 2013-11 Impact factor: 2.759